{"name":"Lundbeck LLC","slug":"lundbeck-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Sabril®","genericName":"Sabril®","slug":"sabril","indication":"Infantile spasms (West syndrome)","status":"marketed"},{"name":"Clobazam High Dose","genericName":"Clobazam High Dose","slug":"clobazam-high-dose","indication":"Seizure disorders / Epilepsy (treatment-resistant or adjunctive therapy)","status":"phase_3"},{"name":"Clobazam Low Dose","genericName":"Clobazam Low Dose","slug":"clobazam-low-dose","indication":"Adjunctive treatment of seizures in epilepsy","status":"phase_3"},{"name":"Clobazam Medium Dose","genericName":"Clobazam Medium Dose","slug":"clobazam-medium-dose","indication":"Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome","status":"phase_3"}]}],"pipeline":[{"name":"Sabril®","genericName":"Sabril®","slug":"sabril","phase":"marketed","mechanism":"Sabril (vigabatrin) irreversibly inhibits GABA transaminase, the enzyme that breaks down the neurotransmitter GABA, thereby increasing GABA levels in the brain.","indications":["Infantile spasms (West syndrome)","Refractory focal seizures as adjunctive therapy"],"catalyst":""},{"name":"Clobazam High Dose","genericName":"Clobazam High Dose","slug":"clobazam-high-dose","phase":"phase_3","mechanism":"Clobazam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to reduce seizure activity.","indications":["Seizure disorders / Epilepsy (treatment-resistant or adjunctive therapy)"],"catalyst":""},{"name":"Clobazam Low Dose","genericName":"Clobazam Low Dose","slug":"clobazam-low-dose","phase":"phase_3","mechanism":"Clobazam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to reduce seizure activity.","indications":["Adjunctive treatment of seizures in epilepsy","Lennox-Gastaut syndrome"],"catalyst":""},{"name":"Clobazam Medium Dose","genericName":"Clobazam Medium Dose","slug":"clobazam-medium-dose","phase":"phase_3","mechanism":"Clobazam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to reduce seizure activity.","indications":["Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome","Adjunctive treatment of focal seizures"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQVlUwVWNaZmJaWXdmblNRbVg0V05JR2FoUWtXUnNiNldObUxYOTEyenc0VmJ0dUsxT2ZBNTVoRmRRS01VN2VvVHM5RWVGM3BlMVdDcjdtdHE4al8xRWxHZzB2MnpSWG9ycGwxQ1NYS05ZOUd0TGdJTGNJdlBiTzFJQ2ZVQUZVVU9nc2dJOThMakJHc1AwRExxRXRKMzVmN2xta25lWkxZMW1RN1E?oc=5","date":"2026-01-22","type":"pipeline","source":"Fierce Pharma","summary":"Lundbeck 'not willing to compromise' on M&A strategy after missed Avadel attempt: exec - Fierce Pharma","headline":"Lundbeck 'not willing to compromise' on M&A strategy after missed Avadel attempt: exec","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOTFdjaXZZYUFMZzNDTjBqcENrS180bzgyZEszNE5HdmRwV3lqWFd2REtkUXhGcFc3clVnaEtLMkszc2k0eE1talVwTk9LVmF3NnFVZ3ZfUm9ELTA5NkVrQy1BWGFURWc5bXVCM3V0NjVlSVBZZ29YSEVJcnRhVG4tMlBLZGY1NGdJZWVVSGVaaTB1TDh4NkZXb2FRN3JHS0N1WmN3Qi1HcWVPVVhBeHFsdXlvVUFkVjdzX05ST3BrM3VSYmtSLVE?oc=5","date":"2025-12-01","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Lundbeck Ends Bidding War for Avadel, After Alkermes’ Up-to-$2.37B Offer - Genetic Engineering and Biotechnology News","headline":"Lundbeck Ends Bidding War for Avadel, After Alkermes’ Up-to-$2.37B Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9LNFNQZWEtYjVlWGxqZ0VtYmktYnQtZ1E1d1VLNkl5MDI5ck5NOHZTc29PZXpZejluQ3B1OURIN3RKWkZucUh0RWVWQS1Sek4tMTBz?oc=5","date":"2025-11-26","type":"pipeline","source":"FirstWord Pharma","summary":"Lundbeck bows out of Avadel pursuit days after Alkermes upped its bid - FirstWord Pharma","headline":"Lundbeck bows out of Avadel pursuit days after Alkermes upped its bid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNYWxpak1UUkkyN2pDSFlIeDI5WmVnM0tVZ2pGT1RMS21DcnVRcWtEZHFrekNfWS05OUdsWElTODFVLWRkVENuYmZXdzNJTDhSX3hHNWw0dVJRaWhoTU5KczV3c3VON19fR1pRWmlkUmd2ZFFHZXNRWTNNRW95N0tBZEY3SXctaXNIc0RYS2l6ZGg2bkVSUUI5TE9CZ3lRM2prQTM0SlF0Nmk3WTBFOWhWaVg5Y0M?oc=5","date":"2025-11-19","type":"pipeline","source":"BioSpace","summary":"UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck - BioSpace","headline":"UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMW9rQThzSUFlb254elY1VTJlQ1dtbHV6VGVsdFBNV1JMS3ZwWGp2SGRLNThkN2l3Z0lxNUFuT2VkY0pFaGF1a0VSVnQ3bktiNHNFd04yNEJHMmg3WEszdV9oMlc1TVVYZGNtMnVCYmtqbzZjRWNGVXBVVjM1bDgyNU1IVFdrcF9kcFozWkhRdWVSbXF1Ml9fQkc5MDV5bzBUSURTdVlUQ1J3bmlWRnA1bk5RVlp5RV8welEw?oc=5","date":"2025-11-19","type":"pipeline","source":"Reuters","summary":"Avadel board backs Alkermes' higher offer over Lundbeck proposal - Reuters","headline":"Avadel board backs Alkermes' higher offer over Lundbeck proposal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZmhicEppeTc3dFl0WURRMW5MVlAxSTJZZ3VWN0NUS052SFhSWTJmcDdHQkFWVFpoUWhKU19YQk5kRUdmNDdheHZ2MmxHQkc1djlBWFFVdDUxME41YWxUN0lHMjdOdXJvQXZ5WGtxZE5qT3dVNzhMQjlDbmVFZVptZHN1Q2lXNnZReEZJVF85bnBlSHk5dmt5TzNxREh3UFRxaEFSVVdIVXFsSm5rQkR1QnhrZnBZQ2gy?oc=5","date":"2025-11-19","type":"pipeline","source":"The Business Journals","summary":"Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war - The Business Journals","headline":"Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxNeGRYOWVjVXV4a3ZhNTloUDhmOWFGcUJNTXlLS0hMSHN6XzlIQUU0ei01N3BSc1BLR2MyeXBKMzFMYnNoQnl0elh2UjBsaU00VjFYb2FQVzVfYWx0NTVwZHRyUzVvUi15Tm9pVmtobjBDOUU0T19YUDNqdFRVYjcxMTFpQlhlMzZYbXo2SEJyWTMxY2VFeWRjZ3gwSnlySldGTnJaWkdFNkNTT1Qxd3NLVkp0Nl80MjBRdWRhY2xYYlpkOGdxVXRKVXpqSGYwSm5Qd1laSjY1ZlEyTE9ScFJORGZkYzVUczkxcjh6MXFVX3dYdDlpRVVIZWIzWjNwM2hF?oc=5","date":"2025-11-17","type":"pipeline","source":"Quiver Quantitative","summary":"Lundbeck Proposes Acquisition of Avadel Pharmaceuticals at Up to $23.00 per Share, Valuing the Company at Approximately $2.4 Billion - Quiver Quantitative","headline":"Lundbeck Proposes Acquisition of Avadel Pharmaceuticals at Up to $23.00 per Share, Valuing the Company at Approximately ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQZzdldGNmZS1aUThCdUh4Mkl6WGE5MU5Ub0kxc3dBd3JRcXNYaE4yVUhOR2dmbEozNTlKVmVyNnNMVjhDRDNZV2ZTTDI4QjRTTG5tTHpDV0R4Mk1hWGZpdy1DSXNPQVFjUHpNMmFtQ0JsSWRWREhLdmhydndLWUFoelVQTzMwbTIwaVdJaWdQeURWb2VocldQZVl1YjBaODRTVXIw?oc=5","date":"2025-11-14","type":"pipeline","source":"Fierce Pharma","summary":"Lundbeck disrupts Alkermes' planned $2.1B purchase of Avadel with higher bid - Fierce Pharma","headline":"Lundbeck disrupts Alkermes' planned $2.1B purchase of Avadel with higher bid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNWWgwNFZnQ3JycF9zMjlIOHdUcUhCenVHQ0YxbDhNbGVNaDl2ckJGXzZKNUYweFRYcHRqRFNWaUk5TmZXZUdyY2JXLUVqelp3bmhLRXo2T1o0UzF0X1hITmJuSERwZWd6cUVkdFpVVXBfS0EwVzZFWGZORzBHTFBpV0ExTGpjWjlJeTc0dk5kZGx2MEFSUmNtOFBKVEQ?oc=5","date":"2025-11-14","type":"deal","source":"Investor's Business Daily","summary":"A New Buyout Battle Is Brewing In Biotech; One Stock Is Up 20% - Investor's Business Daily","headline":"A New Buyout Battle Is Brewing In Biotech; One Stock Is Up 20% - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9YWXY1MTUxNm5NUWwtUkRRVXA5YlBYbjZFOHFaeVVrN2cyblpoSTNtUHdETkwxQ2pPcmQ0SFJxZ21CVWVPZS1qMmUzU2JNQlJFUHJN?oc=5","date":"2025-11-14","type":"pipeline","source":"FirstWord Pharma","summary":"Lundbeck tries to upend Alkermes' takeout of sleep drug developer Avadel - FirstWord Pharma","headline":"Lundbeck tries to upend Alkermes' takeout of sleep drug developer Avadel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPY04xeVBmZHUzQU15RmRnQnFkQm1VekRHeERQaWQ5aGFuTGlHV2Q1TE8zR0ZWaFh4VEJTM0g4dXY1STZ2UVY0WVJ1OVlGTld5ZWNKM0pod0NDcUZTdXpOc25kdkxRWGVvaGNBVXZzNEZ5UUpzRVFoQ2dweGdjN3pNTGZFWVg3UHZRc3VWd05JYWlTQTE1c3Vob3l2X1R6MVd6?oc=5","date":"2025-09-10","type":"pipeline","source":"Pharmaceutical Executive","summary":"Lundbeck Announces Restructuring Plans that will Impact Over 600 International Employees - Pharmaceutical Executive","headline":"Lundbeck Announces Restructuring Plans that will Impact Over 600 International Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxObDFlSzRzRVNielp3ZW5uVHdLNkE1dWlIejZUdF9CaGZxdExkWXpnaGMwcFBMMkVkLUhmbDhJX3VCdVVhdDZNZk9pWFo4Zkk1cG5qTG5nM3g3S2QzLXRWSXhFVzhTUUdwclBvRktPVXpDTkxOR1hBOHphemtIZEhTSVZXWU9FMklfOUxhTDEyM3FrVXh0Q1FiUnlQSllJc1AySFB6QjU3VGxPbFgtYVA0VnVXWm5DRlhmN2lsVnNDY2h0QVJTdDZfVE01OG5ZUFFOUEU4RVdsTnl4cHl4YXg3X2NYaTNXbEV6dHp3Zk4yWmFmVFBJVDNMRlY1dkVmSFBpdkE?oc=5","date":"2024-10-14","type":"deal","source":"businesswire.com","summary":"Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline - businesswire.com","headline":"Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":1,"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}